The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy.

Diabetes mellitus is a complex disease with several metabolic abnormalities leading to varied, interconnected endothelial and vascular dysfunction and resulting in accelerated atherosclerosis. Cardiovascular disease is the main cause of mortality in patients with diabetes. Apart from traditional therapy for control of hyperglycemia and other associated comorbidities, various newer therapies are being investigated to fight atherosclerosis at a molecular level. In this review, the authors briefly describe the pathophysiology of cardiovascular disease in patients with diabetes mellitus and the future of therapy.

[1]  D. Faxon,et al.  Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. , 1996, The Journal of clinical investigation.

[2]  W. Pryor,et al.  Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. , 1992, Chemical research in toxicology.

[3]  J. Tu,et al.  Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study , 2006, The Lancet.

[4]  K. Forrest,et al.  Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. , 2003, Diabetes care.

[5]  M. Harris,et al.  Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971–1993 , 1998, Diabetes Care.

[6]  P. Dicorleto,et al.  Mechanisms of monocyte recruitment and accumulation. , 1993, British heart journal.

[7]  M. Brownlee,et al.  Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.

[8]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[9]  M. Meier,et al.  Protein kinase C activation and its pharmacological inhibition in vascular disease , 2000, Vascular medicine.

[10]  Seppo Lehto,et al.  Gender difference in the impact of type 2 diabetes on coronary heart disease risk. , 2004, Diabetes care.

[11]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Vinik,et al.  Platelet dysfunction in type 2 diabetes. , 2001, Diabetes care.

[13]  R. Torella,et al.  Blood glucose may condition factor VII levels in diabetic and normal subjects , 1988, Diabetologia.

[14]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[15]  G. King,et al.  Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[17]  B. Miskin,et al.  The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus , 2001, Coronary artery disease.

[18]  I. G. Fantus,et al.  Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  W D Wagner,et al.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[21]  H. Gerlach,et al.  Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.

[22]  S. Rössner,et al.  Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. , 1998, The American journal of clinical nutrition.

[23]  G. King,et al.  Protein kinase C activation and the development of diabetic complications. , 1998, Diabetes.

[24]  J. Plutzky.  The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. , 2003, The American journal of cardiology.

[25]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[26]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[27]  A. Ceriello,et al.  Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects , 1993, Diabetologia.

[28]  J. Jukema,et al.  Dual PPAR&agr;/&ggr; Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice , 2006 .

[29]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[30]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[31]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[32]  R. D'Agostino,et al.  The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. , 2004, Diabetes care.

[33]  J. Wautier,et al.  Advanced glycation end products, their receptors and diabetic angiopathy. , 2001, Diabetes & metabolism.

[34]  Joseph T. Brozinick,et al.  A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia , 2005 .

[35]  A. Avogaro,et al.  Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. , 1999, Diabetes.

[36]  W C Willett,et al.  The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. , 2001, Archives of internal medicine.

[37]  A. Pfeiffer,et al.  Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro , 2001, Diabetologia.

[38]  A. Malik,et al.  Increased endothelial albumin permeability mediated by protein kinase C activation. , 1990, The Journal of clinical investigation.

[39]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[40]  R. Hoffmann,et al.  Effect of pioglitazone on vascular reactivity in vivo and in vitro. , 1996, The American journal of physiology.

[41]  V. Jakuš,et al.  Advanced glycation end-products and the progress of diabetic vascular complications. , 2004, Physiological research.

[42]  A. Aljada,et al.  Insulin Inhibits Intranuclear Nuclear Factor κB and Stimulates IκB in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect? , 2001 .

[43]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[44]  A. Barnett,et al.  DPP‐4 inhibitors and their potential role in the management of type 2 diabetes , 2006, International journal of clinical practice.

[45]  M. Navab,et al.  Monocyte adhesion and transmigration in atherosclerosis. , 1994, Coronary artery disease.

[46]  K. Moulder,et al.  Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.

[47]  C. Erem,et al.  Coagulation and Fibrinolysis Parameters in Type 2 Diabetic Patients with and without Diabetic Vascular Complications , 2004, Medical Principles and Practice.

[48]  T. Lyons,et al.  Glycosylation of Low-Density Lipoprotein Enhances Cholesteryl Ester Synthesis in Human Monocyte-Derived Macrophages , 1988, Diabetes.

[49]  M Duriez,et al.  Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[51]  P. Aiello.  The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. , 2005, Diabetes.

[52]  Ernesto L. Schiffrin,et al.  Endothelial dysfunction. , 2004, Journal of the American Society of Nephrology : JASN.

[53]  Mark Woodward,et al.  Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies , 2005, BMJ : British Medical Journal.

[54]  Y. Tseng,et al.  Aminoguanidine Prevents Fructose-Induced Arterial Stiffening in Wistar Rats: Aortic Impedance Analysis , 2004, Experimental biology and medicine.

[55]  T. Watanabe,et al.  Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. , 1999, Biochemical and biophysical research communications.

[56]  H. Vlassara.  Advanced glycation end-products and atherosclerosis. , 1996, Annals of medicine.

[57]  Ann Marie Schmidt,et al.  Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.

[58]  V. Fuster,et al.  Coronary Composition and Macrophage Infiltration in Atherectomy Specimens From Patients With Diabetes Mellitus , 2000, Circulation.

[59]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[60]  S. Haffner,et al.  Insulin resistance implications for type II diabetes mellitus and coronary heart disease. , 1997, The American journal of medicine.

[61]  V. Salomaa,et al.  Impact of Diabetes on Mortality After the First Myocardial Infarction , 1998, Diabetes Care.

[62]  G. King,et al.  Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. , 2000, Diabetes.

[63]  Mark E. Williams,et al.  Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy , 2004, American Journal of Nephrology.

[64]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[65]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[66]  J. Kaski,et al.  The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. , 2003, Journal of the American College of Cardiology.

[67]  J. Plutzky.  PPARs as Therapeutic Targets: Reverse Cardiology? , 2003, Science.

[68]  R. Emkey.  Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. , 2004, MedGenMed : Medscape general medicine.